quinazolines has been researched along with ranitidine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aratani, T; Ito, Y; Kato, H; Morikawa, K; Oshita, M | 1 |
| Ancha, HB; Ancha, HR; Harty, RF; Tedesco, DS; Ward, AR | 1 |
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Abt, M; Ducray, PS; Giraudon, M; Hamilton, M; Kletzl, H; Lum, BL | 1 |
| Masson, E; Tang, W; Tomkinson, H | 1 |
3 trial(s) available for quinazolines and ranitidine
| Article | Year |
|---|---|
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Ranitidine; Young Adult | 2015 |
Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
Topics: Area Under Curve; Biological Availability; Cross-Over Studies; Gefitinib; Healthy Volunteers; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Least-Squares Analysis; Male; Quinazolines; Random Allocation; Ranitidine; Stomach | 2017 |
3 other study(ies) available for quinazolines and ranitidine
| Article | Year |
|---|---|
Pharmacological studies of 2-(3-(3-(1-piperidinylmethyl)-phenoxy)propylamino)-4 (3H)-quinazolinone (NO-794), a new histamine H2-receptor antagonist.
Topics: Animals; Cyclic AMP; Gastric Acid; Gastric Mucosa; Guinea Pigs; Heart Rate; Histamine H2 Antagonists; In Vitro Techniques; Ligation; Male; Phenoxypropanolamines; Pylorus; Quinazolines; Quinazolinones; Ranitidine | 1986 |
Inhibition of epidermal growth factor receptor activation enhances in vivo histamine-stimulated gastric acid secretion in the rat.
Topics: Animals; ErbB Receptors; Gastric Acid; Histamine; Histamine H2 Antagonists; Male; Phosphorylation; Quinazolines; Ranitidine; Rats; Rats, Sprague-Dawley; Transforming Growth Factor alpha; Tyrphostins | 2006 |
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |